| Ofatumumab in AQP4-IgG Seropositive NMOSD (NCT05504694) | Tang-Du Hospital | 2022-06-28 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD (NCT05346354) | Alexion Pharmaceuticals, Inc. | 2022-06-23 |
| A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (NCT05284175) | Peking Union Medical College Hospital | 2022-04-01 |
| CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT04886492) | CorEvitas | 2021-04-28 |
| A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT04660539) | Hoffmann-La Roche | 2021-03-02 |
| Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (NCT04561557) | Tongji Hospital | 2020-09-22 |
| Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) (NCT05017142) | University of Bern | 2020-04-14 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder (NCT04155424) | Alexion Pharmaceuticals, Inc. | 2020-01-14 |
| An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD (NCT04201262) | Alexion Pharmaceuticals, Inc. | 2019-12-09 |
| Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders (NCT04064944) | Third Affiliated Hospital, Sun Yat-Sen University | 2019-09-01 |
| French Registry for Monitoring Pregnancies for Multiple Sclerosis (NCT03900221) | Hospices Civils de Lyon | 2019-08-12 |
| Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital (NCT03819413) | Assiut University | 2019-02-15 |
| Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 (NCT03605238) | Chinese PLA General Hospital | 2018-08-15 |
| Central Pain Study for ABX-1431 (NCT03138421) | Abide Therapeutics | 2017-08-01 |
| Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses (NCT02276963) | Johns Hopkins University | 2016-01-01 |
| Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder (NCT02893111) | Tianjin Medical University General Hospital | 2015-12-01 |
| Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients (NCT03002038) | Isfahan University of Medical Sciences | 2015-09-01 |
| An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients (NCT02003144) | Alexion Pharmaceuticals, Inc. | 2015-01-12 |
| A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) (NCT01892345) | Alexion Pharmaceuticals, Inc. | 2014-04-11 |
| Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) (NCT04256252) | Tang-Du Hospital | 2014-04-01 |
| Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (NCT01777412) | Johns Hopkins University | 2013-06-01 |
| Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (NCT01845584) | Nihon Pharmaceutical Co., Ltd | 2013-05-01 |
| The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders (NCT01623076) | University of Texas Southwestern Medical Center | 2012-06-01 |
| Maintenance Plasma Exchange for Neuromyelitis Optica (NCT01500681) | Mayo Clinic | 2012-06-01 |